AstraZeneca Closes Amyloidosis Gap On Alnylam After Eplontersen Win
Positive Phase III For Ionis-Partnered Antisense Candidate
AstraZeneca is preparing a US filing for hereditary transthyretin-mediated amyloid polyneuropathy for eplontersen, which it hopes will compete with Pfizer and Alnylam's therapies in that rare disease space.
You may also be interested in...
Alnylam has scrapped plans for an interim analysis of its all-important HELIOS-B study of its new ATTR therapy, hoping that a 2024 readout will be more compelling, while the US Inflation Reduction Act has put the brakes on development in another indication.
The company won approval in hATTR amyloidosis polyneuropathy for the RNAi drug, which offers quarterly subcutaneous dosing versus Onpattro’s I.V. administration every three weeks.
AstraZeneca's SGLT2 inhibitor Farxiga could soon get approval as an option for all heart failure patients following the success of the large Phase III DELIVER trial in people with preserved ejection fraction.